Evaluating the effects of GLP-1 analog, oral semaglutide, as a treatment for sporadic behavioral variant frontotemporal dementia (bvFTD)

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
Paul
Principal Investigator Last Name
Edison
Awardee Organization
Awardee State
Contact PI Country
Project Detail
Funding Opportunity Announcement
FY Overall Cost
$2,000,000
Funding Organization
Agency/Funding Organization
Funding Organization Country
Program Official